Back to all studies
RecruitingACTRN12618000106235

The Adjunctive Lithium for Acute Suicide prevention (ALiAS) study: A controlled study examining the effect of adjunctive lithium on acute Suicide prevention in people with a mood disorder

The registry lists this study as recruiting. Study locations are listed in Australia. Confirm recruitment at each site. It focuses on Suicide prevention.

SuicidalityDrugFrom 18 Years to 65 Years
In plain English

Key information made simple

What the source says

The registry describes this research topic: “The ALiAS Trial: Examining the potential for lithium treatment to help patients with suicidality”. This is an interventional study. The registry lists a target sample size of 120. Recruitment status at the registry update of 2018-09-04: recruiting. Read the original description and eligibility criteria, and confirm the practical details with the study team.

What should you check before joining?

Check the full criteria in the official source. Ask the team to confirm recruitment, locations, visits, risks and participation requirements.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateMarch 1, 2018
Recruitment status
Recruiting
Enrollment listed in the registry
120
Sponsor
The University of Sydney
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Australia
Age range
From 18 Years to 65 Years
Official registry ID
ACTRN12618000106235
Official title
The Adjunctive Lithium for Acute Suicidality (ALiAS) Trial: A randomised controlled trial examining the effect of adjunctive lithium on acute suicidality in patients with a mood disorder

Want help reviewing this study?

Loading the security check...
Study ID: ACTRN12618000106235. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Australia · 2 sites
  • Royal North Shore Hospital
    St Leonards
    Site status: Not listed — confirm with the team
  • Northside Clinic Private Hospital
    Greenwich
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with suicide prevention. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. Phase 4 studies usually happen after treatment approval, to monitor real-world use.

Who might this study be for?

This study may concern people with suicide prevention; age range: From 18 Years to 65 Years. The criteria appear strict, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Will I need to change, stop, or stabilize my current treatment?

The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by The University of Sydney, which appears to be a university. The listed contact or investigator is Tim Outhred. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.